Company press releases

Displaying 501 - 512 of 512 results
Released Company Title Industry Topic
17 May 2021
16:00 CEST 		SANOFI Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children 20103015 Pharmaceuticals Other subject
17 May 2021
16:00 CEST 		SANOFI Les données d’un essai pivot présentées au Congrès 2021 de l’ATS montrent que Dupixent® (dupilumab) réduit significativement les crises d’asthme chez l’enfant et améliore sa fonction respiratoire 20103015 Pharmaceuticals Other subject
17 May 2021
07:30 CEST 		SANOFI L’essai de phase II du candidat-vaccin contre la COVID-19 de Sanofi et GSK induit une forte réponse immunitaire chez les adultes, toutes tranches d’âge confondues   20103015 Pharmaceuticals Other subject
17 May 2021
07:30 CEST 		SANOFI Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial 20103015 Pharmaceuticals Other subject
06 May 2021
07:00 CEST 		SANOFI Sanofi noue une collaboration de trois ans avec Stanford Medicine pour intensifier sa recherche en immunologie  20103015 Pharmaceuticals Other subject
06 May 2021
07:00 CEST 		SANOFI Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research 20103015 Pharmaceuticals Other subject
03 May 2021
18:00 CEST 		SANOFI Sanofi: Informations relatives au nombre total de droits de vote et d’actions - Mars 2021 20103015 Pharmaceuticals Share history
03 May 2021
18:00 CEST 		SANOFI Sanofi: Information concerning the total number of voting rights and shares - March 2021 20103015 Pharmaceuticals Share history
30 Apr 2021
17:56 CEST 		SANOFI Annual General Meeting of April 30, 2021 20103015 Pharmaceuticals General meeting / Board Meeting
30 Apr 2021
17:56 CEST 		SANOFI Assemblée Générale Annuelle du 30 avril 2021 20103015 Pharmaceuticals General meeting / Board Meeting
28 Apr 2021
07:30 CEST 		SANOFI Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER 20103015 Pharmaceuticals Other subject
28 Apr 2021
07:30 CEST 		SANOFI Sanofi poursuit sa trajectoire de croissance. Forte hausse du BNPA des activités(1) au T1 2021 à TCC 20103015 Pharmaceuticals Other subject